Hosted on MSN7d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Investing8d
William Blair starts Mersana stock with Outperform rating
The analyst from William Blair highlighted that despite previous challenges, such as the discontinuation of Mersana's former lead program, upifitamab rilsodotin (UpRi), the company's next ...
Nasdaq16d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ...
Investing8d
William Blair starts Mersana stock with Outperform rating
The analyst from William Blair highlighted that despite previous challenges, such as the discontinuation of Mersana's former lead program, upifitamab rilsodotin (UpRi), the company's next-generation ...
The Pharma Letter5d
Mersana Therapeutics
Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...
Yahoo Finance6d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
Business Insider8d
Mersana Therapeutics initiated with an Outperform at William Blair
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes Mersana offers investors a risk/reward skewed to the ...
Business Insider7d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Yahoo Finance13d
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
manilatimes6d
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Finanznachrichten6d
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...